Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).
Pestalozzi BC, et al. Among authors: borner m.
BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.
BMC Cancer. 2017.
PMID: 28407750
Free PMC article.